RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Scientists performed transcriptional profiling of tumors from a Phase II clinical trial of platinum chemotherapy for advanced TNBC, revealing a gene expression signature that identified de novo chemorefractory tumors.